![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
ALISPORIVIR (ALV) PLUS Peg-IFN/RBV (PR) HAS 100% SVR IN IL28B rs12979860 CC ALLELE AND SUPERIOR EFFICACY IN CHRONIC HEPATITIS C GENOTYPE (G) 1 TREATMENT-NAIVE PATIENTS COMPARED WITH PR: THE ESSENTIAL STUDY
|
|
|
Reported by Jules Levin
APASL 2012; 16-19 February 2012; Taipei, Taiwan ROC
R FLISIAK,1 S ZEUZEM,2 J-M PAWLOTSKY,3 PI CALISTRU,4 M JABLKOWSKI,5 D HAUSSINGER,6 G MAZZELLA,7 G VUAGNIAUX,8 R CRABBE,8 C AVILA9
1MEDICAL UNIVERSITY OF BIALYSTOK, POLAND; 2DEPT OF INTERNAL MEDICINE I, JW GOETHE UNIVERSITY HOSPITAL, FRANKFURT/MAIN, GERMANY; 3HOPITAL HENRI MONDOR, CRETEIL, FRANCE; 4CENTRUL DE DIAGNOSTIC SI TRATAMENT DR VIKTOR BABES, BUCHAREST, ROMANIA;
5DEPT OF INFECTIOUS DISEASES, LODZ, POLAND; 6UNIVERSITATSKLINIKUM, DUSSELDORF, GERMANY; 7DEPT OF INTERNAL MEDICINE AND GASTROENTEROLOGY, UNIVERSITY OF BOLOGNA, ITALY; 8DEBIOPHARM, LAUSANNE, SWITZERLAND; 9NOVARTIS, BASEL, SWITZERLAND
![APSL1.gif](../images/022212/022212-3/APSL1.gif)
![APSL2.gif](../images/022212/022212-3/APSL2.gif)
![APSL3.gif](../images/022212/022212-3/APSL3.gif)
![APSL4.gif](../images/022212/022212-3/APSL4.gif)
![APSL5.gif](../images/022212/022212-3/APSL5.gif)
![APSL6.gif](../images/022212/022212-3/APSL6.gif)
![APSL7.gif](../images/022212/022212-3/APSL7.gif)
![APSL8.gif](../images/022212/022212-3/APSL8.gif)
![APSL9.gif](../images/022212/022212-3/APSL9.gif)
References
1. Flisiak R et al. Hepatology. 2009;49:1460-8.
2. Ge D et al. Nature. 2009;461:399-401.
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|